



SUPPLEMENTARY FIGURES

Supplementary Figure 1. Multiplex immunofluorescence markers by pathological complete response in patients treated with chemotherapy plus atezolizumab.




Supplementary Figure 1. Pathological complete response by multiplex immunofluorescence markers in patients treated with chemotherapy plus atezolizumab. Green areas represent pathological complete responses and blue areas represent non-pathological complete responses. (S1 A) Demonstrates CD8+ density cells/mm² in the chemotherapy plus atezolizumab, Arm B, p=0.25. (S1 B) CD8+PD1+ density cells/mm² in Arm B, p=0.33. (S1 C) FOXP3+ density cells/mm² in Arm B, p=0.48. The box stands for the interquartile range, the bar inside a box represents the median, and the whiskers represent 5th and 95th percentiles.

Supplementary Figure 2. Pathological complete response by menopausal status in patients treated with chemotherapy plus atezolizumab.



Supplementary Figure 2 Pathological complete response by menopausal status in patients treated with chemotherapy plus atezolizumab, $p=0.24$. Error bars represent standard error of pCR rate.

Supplementary Figure 3. Pathological complete response by nodal status in patients treated with chemotherapy plus atezolizumab.



Supplementary Figure 3. Pathological complete response by nodal status in patients treated with chemotherapy plus atezolizumab, $p > 0.99$. Error bars represent standard error of pCR rate.